PubMed:9229602 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/9229602","sourcedb":"PubMed","sourceid":"9229602","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/9229602","text":"[Antazoline/tetryzoline eyedrops in comparison with levocabastine eyedrops in acute allergic conjunctivitis].\nAntazolin/Tetryzolinhaltige Augentropfen im Vergleich zu Levocabastinhaltigen Augentropfen bei akuter allergischer Konjunktivitis.\nBACKGROUND: Allergic conjunctivitis is one of the most frequent allergic diseases of the anterior eye segment.\nMETHODS: This multicentre, clinical trial was an investigation to compare the antiallergic efficacy, local tolerance and safety of Antazolin/Tetryzolin eye drops and Levocabastine eye drops. 69 patients were treated over a 2 weeks course of therapy. The subjective and objective ocular symptoms were documented over the treatment period.\nRESULTS: Both eye drops reduced subjective and objective ocular symptoms effective. The difference between the treatments (p = 0.0395) was the faster onset of action of Antazolin/Tetryzolin 30 minutes after administration of the first drop of trial medication.\nCONCLUSION: A fast and effective onset of action is of high clinical relevance. Therefore the benefits of using Antazolin/Tetryzolin eye drops was clearly outweigh.","tracks":[]}